Effect of Resveratrol on Walking in Older People With PAD
Does resveratrol improve the 6-minute walk performance in patients with peripheral artery disease (PAD)?
In a parallel design, double-blind, pilot, randomized clinical trial (RESTORE), 66 patients aged ≥65 years with PAD were randomized to receive daily resveratrol at 125 mg, 500 mg, or placebo for 6 months. The primary outcome measure was the change in 6-minute walk distance from baseline to 6 months of follow-up. Secondary outcomes included change in maximal treadmill walking time.
The 66 participants were predominantly men (45 [68%]) with a mean (standard deviation) age of 74.4 (6.6) years and a mean ankle-brachial index of 0.67 (0.18). Six-month mean (SE) change in 6-minute walk distance was -12.3 (7.9) meters for the placebo group, 4.6 (8.1) meters for the 125-mg resveratrol group (p = 0.07 vs. placebo), and -12.8 (7.5) meters for the 500-mg resveratrol group (p = 0.96 vs. placebo). Six-month mean (SE) change in maximal treadmill walking time was 0.4 (2.1) minutes for the placebo group, 0.5 (2.3) minutes for the 125-mg resveratrol group (p = 0.18 vs. placebo), and -0.6 (2.1) minutes for the 500-mg resveratrol group (p = 0.12 vs. placebo).
The authors concluded that the RESTORE trial found no consistent evidence that resveratrol improves walking performance in older patients with PAD.
To date, only one medication (cilostazol) is guideline-recommended to improve walking distance in patients with PAD (J Am Coll Cardiol 2017;69:e71-e126). This study was unable to demonstrate an association between resveratrol use and increased walking ability. Perhaps more important to note is that a minority of patients (only 29%) reported walking for exercise 3 or more times weekly. As one of the most effective therapies for improving walking function, clinicians should encourage all patients with PAD to engage in regular supervised or structured community- or home-based walking exercise.
Keywords: Ankle Brachial Index, Exercise Test, Exercise Therapy, Geriatrics, Mobility Limitation, Outcome Assessment (Health Care), Peripheral Arterial Disease, Primary Prevention, Vascular Diseases, Walking
< Back to Listings